Novartis
Helping Create a Healthier and Safer World

Pharmacovigilance is regarded as the constant process of identifying the safe use of pharmaceutical products and helps in minimizing the risk of any harm that may come to patients. Pharma Companies must conduct a comprehensive drug safety and pharmacovigilance audit to assess their compliance with worldwide laws, regulations, and FDA guidance. However, the occurrence of an adverse event is not always during a visit to the healthcare center. It can occur after several hours of administering the drug. Patients fail to remember all the relevant information about adverse events and are not able to report it accurately. At this point, Novartis helps companies develop strategies that build leading, focused, medicines powered by advanced therapy platforms and data science. Moreover, the company also transforms the internal culture within companies to ensure that people can fully apply their talent and energy towards creating a more driven and focused Novartis.

Novartis Pharmaceuticals brings innovative medicines to market to enhance health outcomes for patients and offer solutions to the healthcare providers who treat them. The organization’s purpose is to reimagine medicine such that it improves and extends people's lives. “We use innovative science and technology to address some of society's most challenging healthcare issues,” says Vasant Narasimhan, CEO of Novartis. Novartis discovers and develops breakthrough treatments and finds new ways to deliver them to as many people as possible. The company also aims to reward those who invest their money, time and ideas into developing new age healthcare.

Novartis is structured to deliver innovative products, leverage global scale, and respond to new opportunities and risks.

Our divisions - Innovative Medicines and Sandoz - are supported by functional organizations with global scale.

Made up of two business units, Novartis Pharmaceuticals includes Novartis Gene Therapies, and Novartis Oncology – the company’s Innovative Medicines Division which commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Benefitting from a continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide.

The organization offers about 1,000 generic medicines and biosimilars covering major therapeutic areas. It can also help clients bring substantial savings to patients and healthcare systems and help improve access to healthcare. Through Novartis Gene Therapies, the company also explores advanced therapy platforms such as genes and therapeutic viruses including Adeno-associated viruses (AAVs) in neuroscience, as well as potential treatments for Rett syndrome, a genetic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. The pharmaceutical organization’s current portfolio includes more than 50 key marketed products, many of which are leaders in their respective therapeutic areas. Global Program Management drives the planning and execution of drug development programs and provides the information the enterprise needs to make the right portfolio decisions. GPM associates enable the cross-functional Global Program Teams (GPTs) to deliver the pipeline with optimal strategies, realistic plans, and seamless execution.

Novartis consistently demonstrates the drive, self-motivation, and eagerness to learn and succeed within the various disciplines offered, including early clinical development/translational medicine, clinical development, regulatory affairs, medical affairs, and commercial strategy and brand marketing.